Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S-P Choo

Showing results (1-10 of 18) with videos related to

Pageof 2
Sort By:
Biochemical Society Transactions|November 1, 1995
NADH oxidoreductase activity in human and mouse cells treated with free radical generating agentsS Brown, V Fletcher, S P Choo
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 28, 2009
Travel warning with capecitabineM Wong, S-P Choo, E-H Tan
ESMO Open|April 22, 2021
Locoregional therapy in hepatocellular carcinoma: when to start and when to stop and when to revisitJ J X Lee, D W-M Tai, S P Choo
Current Cancer Drug Targets|August 13, 2011
Comparing the efficacy of sunitinib with sorafenib in xenograft models of human hepatocellular carcinoma: mechanistic explanationH Huynh, S P Choo, H C Toh, et al.
ESMO Gastrointestinal Oncology|February 6, 2026
Consensus statement on the use of systemic therapies in pancreatic ductal adenocarcinoma in AsiaD-Y Oh, B Shen, S Satoi, et al.
European Journal of Cancer (Oxford, England : 1990)|December 26, 2012
A Phase 1 dose-finding and pharmacodynamic study of rapamycin in combination with bevacizumab in patients with unresectable hepatocellular carcinomaS P Choo, B Chowbay, Q S Ng, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 27, 2023
Nivolumab in sorafenib-naive and sorafenib-experienced patients with advanced hepatocellular carcinoma: 5-year follow-up from CheckMate 040A B El-Khoueiry, J Trojan, T Meyer, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 21, 2013
A randomized, placebo-controlled phase 2 study of ganitumab or conatumumab in combination with FOLFIRI for second-line treatment of mutant KRAS metastatic colorectal cancerA L Cohn, J Tabernero, J Maurel, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 4, 2017
A phase Ib study of selumetinib (AZD6244, ARRY-142886) in combination with sorafenib in advanced hepatocellular carcinoma (HCC)W M Tai, W P Yong, C Lim, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 30, 2016
A phase Ib study of selumetinib (AZD6244, ARRY-142886) in combination with sorafenib in advanced hepatocellular carcinoma (HCC)W M Tai, W P Yong, C Lim, et al.
Pageof 2

Showing results (1-10 of 18) with videos related to

Sort By:
Pageof 2
Biochemical Society Transactions|November 1, 1995
NADH oxidoreductase activity in human and mouse cells treated with free radical generating agentsS Brown, V Fletcher, S P Choo
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 28, 2009
Travel warning with capecitabineM Wong, S-P Choo, E-H Tan
ESMO Open|April 22, 2021
Locoregional therapy in hepatocellular carcinoma: when to start and when to stop and when to revisitJ J X Lee, D W-M Tai, S P Choo
Current Cancer Drug Targets|August 13, 2011
Comparing the efficacy of sunitinib with sorafenib in xenograft models of human hepatocellular carcinoma: mechanistic explanationH Huynh, S P Choo, H C Toh, et al.
ESMO Gastrointestinal Oncology|February 6, 2026
Consensus statement on the use of systemic therapies in pancreatic ductal adenocarcinoma in AsiaD-Y Oh, B Shen, S Satoi, et al.
European Journal of Cancer (Oxford, England : 1990)|December 26, 2012
A Phase 1 dose-finding and pharmacodynamic study of rapamycin in combination with bevacizumab in patients with unresectable hepatocellular carcinomaS P Choo, B Chowbay, Q S Ng, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 27, 2023
Nivolumab in sorafenib-naive and sorafenib-experienced patients with advanced hepatocellular carcinoma: 5-year follow-up from CheckMate 040A B El-Khoueiry, J Trojan, T Meyer, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 21, 2013
A randomized, placebo-controlled phase 2 study of ganitumab or conatumumab in combination with FOLFIRI for second-line treatment of mutant KRAS metastatic colorectal cancerA L Cohn, J Tabernero, J Maurel, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 4, 2017
A phase Ib study of selumetinib (AZD6244, ARRY-142886) in combination with sorafenib in advanced hepatocellular carcinoma (HCC)W M Tai, W P Yong, C Lim, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 30, 2016
A phase Ib study of selumetinib (AZD6244, ARRY-142886) in combination with sorafenib in advanced hepatocellular carcinoma (HCC)W M Tai, W P Yong, C Lim, et al.
Pageof 2